We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

539 hedge funds and large institutions have $11.9B invested in Teva Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 202 increasing their positions, 164 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more call options, than puts

Call options by funds: $589M | Put options by funds: $312M

23% more repeat investments, than reductions

Existing positions increased: 202 | Existing positions reduced: 164

9% more capital invested

Capital invested by funds: $11B → $11.9B (+$977M)

0.53% more ownership

Funds ownership: 62.33% → 62.86% (+0.53%)

4% less funds holding

Funds holding: 560 → 539 (-21)

12% less funds holding in top 10

Funds holding in top 10: 26 → 23 (-3)

22% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 69

Holders
539
Holders Change
-21
Holders Change %
-3.75%
% of All Funds
7.1%
Holding in Top 10
23
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-11.54%
% of All Funds
0.3%
New
54
Increased
202
Reduced
164
Closed
69
Calls
$589M
Puts
$312M
Net Calls
+$277M
Net Calls Change
+$131M

Top Buyers

Rank Fund Capital Flow
1
HIIFS
Harel Insurance Investments & Financial Services
Israel
+$183M
2
PF
Phoenix Financial
Israel
+$166M
3
MMH
Menora Mivtachim Holdings
Israel
+$150M
4
SC
Soundwatch Capital
Connecticut
+$138M
5
PC
PointState Capital
New York
+$90.1M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$397M
2
CI
Clal Insurance
Israel
-$87.6M
3
Millennium Management
Millennium Management
New York
-$70.9M
4
Morgan Stanley
Morgan Stanley
New York
-$70.7M
5
Citigroup
Citigroup
New York
-$47.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
TSMHT
501
Thurston Springer Miller Herd & Titak
Indiana
$2.92K – – –
HWP
502
Highline Wealth Partners
California
$2.77K – – –
GEA
503
Glen Eagle Advisors
New Jersey
$2.68K – – –
BIA
504
Bell Investment Advisors
California
$2.62K – – –
RA
505
Ransom Advisory
Rhode Island
$2.51K – – –
BCMLT
506
Beacon Capital Management LLC (Tennessee)
Tennessee
$2.38K – – –
JGIA
507
Jackson Grant Investment Advisers
Connecticut
$2.04K – – –
WTC
508
WhitTier Trust Company
Nevada
$1.76K – – –
CFFP
509
Center for Financial Planning
Michigan
$1.68K – – –
FWM
510
FSA Wealth Management
Massachusetts
$1.68K – – –
HC
511
Hurley Capital
New York
$1.68K – – –
MA
512
MCF Advisors
Kentucky
$1.68K – – –
MWA
513
Medallion Wealth Advisors
Connecticut
$1.66K – – –
WA
514
Whipplewood Advisors
Colorado
$1.51K +$1.32K +82 +1,025%
1IA
515
1620 Investment Advisors
Massachusetts
$1.37K – – –
LWA
516
Lowe Wealth Advisors
Maryland
$1.14K – – –
VNA
517
Valley National Advisers
Pennsylvania
$1K – – –
SC
518
SouthState Corp
Florida
$989 +$952 +59 New
WWM
519
Wolff Wiese Magana
California
$922 – – –
GA
520
GoalVest Advisory
New York
$905 – – –
CPG
521
Cornerstone Planning Group
New Jersey
$880 +$613 +38 +211%
AP
522
Aspect Partners
Virginia
$838 – – –
DPW
523
DiNuzzo Private Wealth
Pennsylvania
$805 – – –
CA
524
CoreCap Advisors
Michigan
$737 – – –
CFD
525
Creative Financial Designs
Indiana
$737 – – –
19 20
21
22 23

TEVA Hedge Fund Activity: Q2 2025 in Review

539 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2025, worth a combined $11.9B — up 8.9% from $11B a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of TEVA and 54 opened new positions — a net loss of 15 holders — while 164 trimmed existing stakes and 202 added.

The largest buyer was Harel Insurance Investments & Financial Services, adding an estimated $183M. The largest seller was Fidelity Investments, cutting an estimated $397M.

  • 539 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2025, down from 560 in Q1 2025.
  • Funds reported $11.9B of Teva Pharmaceuticals stock for Q2 2025, up 8.9% quarter-over-quarter.
  • 54 funds opened new Teva Pharmaceuticals positions in Q2 2025 and 69 closed out, a net change of -15 holders.
  • The largest Teva Pharmaceuticals buyer in Q2 2025 was Harel Insurance Investments & Financial Services, an estimated $183M added.
  • The largest Teva Pharmaceuticals seller in Q2 2025 was Fidelity Investments, an estimated $397M sold.

Based on aggregated 13F filings for Q2 2025.